Raras
Buscar doenças, sintomas, genes...
Doença da urina xarope de bordo
ORPHA:511CID-10 · E71.0CID-11 · 5C50.D0DOENÇA RARA

Doença hereditária autossômica recessiva causada por mutações nos genes BCKDHA, BCKDHB, DBT e DLD. É caracterizada por uma deficiência do complexo alfa-cetoácido desidrogenase de cadeia ramificada, levando ao acúmulo de metabólitos nos fluidos corporais. O nome da doença deriva do odor adocicado da urina dos bebês, que lembra o xarope de bordo. Os sinais e sintomas geralmente aparecem na infância e incluem letargia e atrasos no desenvolvimento. Se não for tratada, pode causar convulsões, coma e morte.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença hereditária autossômica recessiva causada por mutações nos genes BCKDHA, BCKDHB, DBT e DLD. É caracterizada por uma deficiência do complexo alfa-cetoácido desidrogenase de cadeia ramificada, levando ao acúmulo de metabólitos nos fluidos corporais. O nome da doença deriva do odor adocicado da urina dos bebês, que lembra o xarope de bordo. Os sinais e sintomas geralmente aparecem na infância e incluem letargia e atrasos no desenvolvimento. Se não for tratada, pode causar convulsões, coma e morte.

Pesquisas ativas
5 ensaios
17 total registrados no ClinicalTrials.gov
Publicações científicas
1.347 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Childhood
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 20%
Triagem neonatal (Fase 2)CID-10: E71.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (7)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)nutritional
0301070040
Atendimento em reabilitação — doenças raras
+1 outros procedimentos
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
15 sintomas
🫃
Digestivo
6 sintomas
📏
Crescimento
5 sintomas
❤️
Coração
3 sintomas
💪
Músculos
2 sintomas
🫘
Rins
2 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

90%prev.
Convulsão
Muito frequente (99-80%)
90%prev.
Morfologia anormal da faringe
Muito frequente (99-80%)
90%prev.
Atraso global do desenvolvimento
Muito frequente (99-80%)
90%prev.
Insuficiência respiratória
Muito frequente (99-80%)
90%prev.
Reflexos tendíneos reduzidos
Muito frequente (99-80%)
90%prev.
Níveis plasmáticos elevados de aminoácidos de cadeia ramificada
Muito frequente (99-80%)
62sintomas
Muito frequente (9)
Frequente (2)
Sem dados (51)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 62 características clínicas mais associadas, ordenadas por frequência.

ConvulsãoSeizure
Muito frequente (99-80%)90%
Morfologia anormal da faringeAbnormality of the pharynx
Muito frequente (99-80%)90%
Atraso global do desenvolvimentoGlobal developmental delay
Muito frequente (99-80%)90%
Insuficiência respiratóriaRespiratory insufficiency
Muito frequente (99-80%)90%
Reflexos tendíneos reduzidosReduced tendon reflexes
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.347PubMed
Últimos 10 anos200publicações
Pico202553 papers
Linha do tempo
2026Hoje · 2026🧪 1995Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: MS/MS (espectrometria de massas em tandem)
Fase 2 do PNTNin_rollout
Incidência no Brasil: 1:10.000 (coletivo)

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

DLDDihydrolipoyl dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoamide dehydrogenase is a component of the glycine cleavage system as well as an E3 component of three alpha-ketoacid dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and branched-chain amino acid-dehydrogenase complex) (PubMed:15712224, PubMed:16442803, PubMed:16770810, PubMed:17404228, PubMed:20160912, PubMed:20385101). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also locali

LOCALIZAÇÃO

Mitochondrion matrixNucleusCell projection, cilium, flagellumCytoplasmic vesicle, secretory vesicle, acrosome

VIAS BIOLÓGICAS (10)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyH139Hfs13* PPM1K causes a mild variant of MSUDSignaling by Retinoic Acid
MECANISMO DE DOENÇA

Dihydrolipoamide dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.2 TPM
Coração - Ventrículo esquerdo
70.7 TPM
Músculo esquelético
69.5 TPM
Esôfago - Muscular
69.5 TPM
Glândula adrenal
69.1 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3 deficiency
HGNC:2898UniProt:P09622
DBTLipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme A, acyl groups that are generated by the branched-chain alpha-keto acid decarboxylase component

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Protein lipoylationMitochondrial protein degradation
EXPRESSÃO TECIDUAL(Ubíquo)
Bladder
10.2 TPM
Nervo tibial
8.9 TPM
Glândula adrenal
8.7 TPM
Artéria tibial
8.4 TPM
Fallopian Tube
8.3 TPM
OUTRAS DOENÇAS (5)
maple syrup urine disease type 2intermediate maple syrup urine diseasethiamine-responsive maple syrup urine diseaseintermittent maple syrup urine disease
HGNC:2698UniProt:P11182
PPM1KProtein phosphatase Mn(2+)-dependent 1KDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine-protein phosphatase component of macronutrients metabolism. Forms a functional kinase and phosphatase pair with BCKDK, serving as a metabolic regulatory node that coordinates branched-chain amino acids (BCAAs) with glucose and lipid metabolism via two distinct phosphoprotein targets: mitochondrial BCKDHA subunit of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex and cytosolic ACLY, a lipogenic enzyme of Krebs cycle (PubMed:17336929, PubMed:17374715, PubMed:194117

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Branched-chain amino acid catabolism
MECANISMO DE DOENÇA

Maple syrup urine disease, mild variant

A mild form of maple syrup urine disease, a metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. MSUDMV is characterized by increased plasma levels of branched-chain amino acids (BCAA) apparent at birth. Treatment with a low-protein diet free of BCAA can result in normal psychomotor development and lack of metabolic episodes.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
42.9 TPM
Cervix Ectocervix
41.0 TPM
Útero
41.0 TPM
Fallopian Tube
40.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (2)
maple syrup urine disease, mild variantintermediate maple syrup urine disease
HGNC:25415UniProt:Q8N3J5
BCKDHB2-oxoisovalerate dehydrogenase subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Together with BCKDHA forms the heterotetrameric E1 subunit of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. The BCKD complex catalyzes the multi-step oxidative decarboxylation of alpha-ketoacids derived from the branched-chain amino-acids valine, leucine and isoleucine producing CO2 and acyl-CoA which is subsequently utilized to produce energy. The E1 subunit catalyzes the first step with the decarboxylation of the alpha-ketoacid forming an enzyme-product intermed

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (6)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyLoss-of-function mutations in DLD cause MSUD3/DLDDLoss-of-function mutations in DBT cause MSUD2
MECANISMO DE DOENÇA

Maple syrup urine disease 1B

A form of maple syrup urine disease, an autosomal recessive metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated.

OUTRAS DOENÇAS (4)
maple syrup urine disease type 1Bclassic maple syrup urine diseaseintermittent maple syrup urine diseaseintermediate maple syrup urine disease
HGNC:987UniProt:P21953
BCKDHA2-oxoisovalerate dehydrogenase subunit alpha, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Together with BCKDHB forms the heterotetrameric E1 subunit of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. The BCKD complex catalyzes the multi-step oxidative decarboxylation of alpha-ketoacids derived from the branched-chain amino-acids valine, leucine and isoleucine producing CO2 and acyl-CoA which is subsequently utilized to produce energy. The E1 subunit catalyzes the first step with the decarboxylation of the alpha-ketoacid forming an enzyme-product intermed

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (7)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyLoss-of-function mutations in DLD cause MSUD3/DLDDLoss-of-function mutations in DBT cause MSUD2
MECANISMO DE DOENÇA

Maple syrup urine disease 1A

A form of maple syrup urine disease, an autosomal recessive metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated.

OUTRAS DOENÇAS (4)
maple syrup urine disease type 1Aclassic maple syrup urine diseaseintermediate maple syrup urine diseaseintermittent maple syrup urine disease
HGNC:986UniProt:P12694

Variantes genéticas (ClinVar)

426 variantes patogênicas registradas no ClinVar.

🧬 DLD: NM_000108.5(DLD):c.704_705del (p.Leu235fs) ()
🧬 DLD: NM_000108.5(DLD):c.848dup (p.Lys284fs) ()
🧬 DLD: NM_000108.5(DLD):c.623C>T (p.Ser208Phe) ()
🧬 DLD: NM_000108.5(DLD):c.405_407del (p.Gly137del) ()
🧬 DLD: NM_000108.5(DLD):c.127G>A (p.Asp43Asn) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2,352 variantes classificadas pelo ClinVar.

470
353
1529
Patogênica (20.0%)
VUS (15.0%)
Benigna (65.0%)
VARIANTES MAIS SIGNIFICATIVAS
BCKDHA: NM_000709.4(BCKDHA):c.273dup (p.Ser92fs) [Pathogenic]
DBT: NM_001918.5(DBT):c.224G>A (p.Gly75Glu) [Likely pathogenic]
PPM1K: NM_152542.5(PPM1K):c.586C>T (p.Arg196Ter) [Pathogenic]
DBT: NM_001918.5(DBT):c.51+1G>A [Likely pathogenic]
PPM1K: NM_152542.5(PPM1K):c.212T>C (p.Ile71Thr) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
·Pré-clínico10
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 11 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença da urina xarope de bordo

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

17 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
440 papers (10 anos)
#1

Assessing the nutritional value and health risks of special low‑protein foods: narrative review.

Orphanet journal of rare diseases2026 Mar 06

Special low-protein foods (SLPFs) are essential for patients with disorders of inherited amino acid metabolism that require lifelong dietary protein restriction to prevent severe neurocognitive effects and even death. Conditions such as phenylketonuria (PKU), tyrosinemia (TYR), maple syrup urine disease (MSUD), homocystinuria (HCU), and urea cycle disorders (UCD) depend on these foods to support metabolic control and dietary adherence. SLPFs provide satiety, energy, and help prevent catabolism, but their nutritional composition poses challenges. Most SLPFs are formulated using isolated starches as the primary macronutrient base. Hydrocolloid fibers are commonly added to improve texture, consistency, shelf life, and water or gas retention. These ingredients form the backbone of SLPFs production and are consistently used across different regions worldwide, reflecting a standardized approach to their formulation. However, their potential adverse effects include suppression of gut microbiota, gut dysbiosis, increased inflammatory markers, overweight, and obesity, all of which raise cardio‑metabolic risks. Strengthening the nutritional quality of SLPFs through natural plant sources may help mitigate their potential adverse outcomes while ensuring patients’ dietary needs are met. Therefore, it is important to explore natural low‑protein alternatives that can both support sustainable food production and promote long‑term health benefits.

#2

A risk-based, QTPP-driven framework for semi-solid extrusion 3d printing of personalized medicines: Integrating hospital compounding and clinical trial regulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2026 Jan 01

Semi-solid extrusion (SSE) 3D printing enables precise, patient-specific oral medicines, yet its uptake is constrained by fragmented regulatory pathways. This study develops an applied, risk-based framework grounded in empirical data from hospital compounding and early-phase clinical trial implementation, integrating both within a unified regulatory model through the concept of the printable ink as a pharmaceutical intermediate. Drawing from three pediatric use cases involving 5 different active pharmaceuticals ingredients (APIs), trimethoprim-sulfamethoxazole (Bactrim®), cyclophosphamide, tamoxifen (OPERA clinical trial) and isoleucine (Maple syrup urine disease) the framework applies quality-by-design principles (ICH Q8-Q11, USP <1220>) to define critical quality attributes (CQAs), critical process parameters (CPPs), and in-process controls (IPCs) suitable for both centralized and point-of-care production. Two complementary tables stratify APIs by risk and map them to actionable quality control strategies, enabling science-based decisions on when IPCs alone suffice versus when full GMP oversight is required. This harmonized model supports reproducible, traceable production across decentralized sites, addressing regulatory ambiguity while preserving flexibility for innovation in paediatric and rare disease care.

#3

A case of maple syrup urine disease with infantile epileptic spasms syndrome: Challenges in a resource-limited setting.

Pediatrics international : official journal of the Japan Pediatric Society2026
#4

Alterations in gut microbiota composition in children with methylmalonic acidemia, propionic acidemia, and maple syrup urine disease.

European journal of clinical nutrition2026 Mar 23

Methylmalonic acidemia (MMA), propionic acidemia (PA), and maple syrup urine disease (MSUD) are rare monogenic disorders that are described as intoxication-type inborn errors of metabolism (IEMs). They usually present in early life, and long-term management requires strict dietary protein restriction, which may significantly alter gut microbiota composition. Despite growing interest in microbiome research, limited data exist on gut microbiota in these disorders, and no study is available for MMA and MSUD. We aimed to describe the gut microbiota compositions in children with MMA, PA, and MSUD. A total of eight patients (Five MMA, one PA, and two MSUD), and 11age-matched healthy controls were enrolled. All patients were following a medically supervised, protein-restricted diet. Fecal sample was collected from each participant, and gut microbiota composition was evaluated with 16S rRNA sequencing. Patients with MMA, PA, and MSUD exhibited significantly altered gut microbiota composition compared to healthy controls. Alpha diversity analysis revealed reduced microbial richness in patients, with significantly lower Chao1 and observed OTU indices (p < 0.05). Beta diversity metrics demonstrated distinct clustering between groups, indicating significantly different microbial community structures. Higher relative abundances of opportunistic or dysbiotic taxa have been seen in patient group, while controls were enriched in beneficial taxa like Faecalibacterium prausnitzii, Ruminococcus, and Lactobacillus. LEfSe analysis identified 17 taxa enriched in patients-including members of Proteobacteria, Sphingobacteriia, and Streptococcus anginosus-and 6 taxa enriched in controls, notably Faecalibacterium prausnitzi. This is the first descriptive study of the gut microbiota composition of MMA, PA, and MSUD patients. These findings indicate an association between long-term dietary management and altered microbiota composition, although causality cannot be inferred due to the cross-sectional study design. The observed alterations suggest that the gut microbiota may represent a novel therapeutic target in the management of IEMs.

#5

A Colorimetric Multimetabolite Assay for Quantitative Measurement of Keto Acids in Urine for At-Home Monitoring of Metabolic Disorders.

Journal of analytical methods in chemistry2026

Inborn errors of metabolism such as phenylketonuria (PKU) and maple syrup urine disease (MSUD) can cause severe developmental problems. Both conditions can lead to harmful levels of keto acids in biofluids-phenylpyruvic acid (PPA) in PKU and branched-chain α-keto acids in MSUD. Monitoring urinary keto acids helps track dietary adherence and reduces the risk of metabolic crisis. However, current at-home tests are qualitative and difficult to interpret, while existing metabolomic assays require expensive equipment and must be conducted in a lab. This study aimed to develop a simple, quantitative, rapid, at-home assay for detecting multiple urinary keto acids associated with PKU and MSUD. A modified two-step 2,4-dinitrophenylhydrazine (DNPH)-based multimetabolite assay was developed, where sodium hydroxide (NaOH) converts the yellow hydrazone precipitate to a stable amber solution, enabling quantification of multiple keto acids (700-7200 μM) within 10 min. The assay was validated using spiked urine samples and adapted into a prototype at-home kit using caprolactam-immobilized NaOH. Nuclear magnetic resonance (NMR)-based metabolomics was used as a reference method to authenticate readings from a PKU patient. Correlation studies demonstrated strong linearity for MSUD (R 2 = 0.91-0.96)- and PKU (R 2 = 0.95-0.99)-spiked samples. Quantification of keto acids in authentic PKU urine samples showed excellent agreement with the results of quantitative NMR-based metabolomics assays (R 2 = 0.99). Low-cost, at-home colorimetric tests for urinary keto acids could enable screening, detection, and monitoring of PKU and MSUD in the 90% of the world without access to advanced metabolic clinics.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC842 artigos no totalmostrando 199

2026

Alterations in gut microbiota composition in children with methylmalonic acidemia, propionic acidemia, and maple syrup urine disease.

European journal of clinical nutrition
2026

Assessing the nutritional value and health risks of special low‑protein foods: narrative review.

Orphanet journal of rare diseases
2026

A Colorimetric Multimetabolite Assay for Quantitative Measurement of Keto Acids in Urine for At-Home Monitoring of Metabolic Disorders.

Journal of analytical methods in chemistry
2026

Clinical Profiles, Genetic Variants, and Neurodevelopmental Outcomes Following Liver Transplantation in Maple Syrup Urine Disease: A Study From Palestine.

JIMD reports
2026

A case of maple syrup urine disease with infantile epileptic spasms syndrome: Challenges in a resource-limited setting.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Application of high-resolution mass spectrometry profiling towards the diagnosis and acute management of maple syrup urine disease.

Molecular genetics and metabolism reports
2026

Metformin therapy to facilitate weight loss in adults with classic maple syrup urine disease.

Molecular genetics and metabolism
2025

Congenital Inborn Errors of Metabolism: Clinical and Imaging Pearls.

Radiographics : a review publication of the Radiological Society of North America, Inc
2026

Pediatric Full and In-situ Split Domino Living Donor Liver Transplants Experience.

Transplantation proceedings
2025

Navigating Adulthood with Maple Syrup Urine Disease: Patient and Caregiver Perspectives on Healthcare Transition and Independent Living.

Research square
2025

Pediatric liver transplant for maple syrup urine disease a single center experience.

Frontiers in pediatrics
2025

Expanded Newborn Screening for Inborn Errors of Metabolism at a Single Center in Louisiana (2005-2024): Outcomes.

International journal of neonatal screening
2025

Domino Hepatectomy and Implantation With Innovative Outflow Reconstruction for an Adult Patient With Maple Syrup Urine Disease and Type 1 Diabetes Mellitus: Surgical Technique.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2025

Genetic variability in maple syrup urine disease: novel mutations and their pathogenicity in the Iranian population.

Molecular biology reports
2026

Inflammation in maple syrup urine disease.

Clinica chimica acta; international journal of clinical chemistry
2025

Cerebral edema in maple syrup urine disease: spectrum of clinical presentation and treatment outcomes.

Orphanet journal of rare diseases
2025

Nutritional management of metabolic disorders in neonates and infants in Saudi Arabia: consensus recommendations.

Orphanet journal of rare diseases
2025

Design and pharmacodynamic study of live biotherapeutic products with efficient degradation of branched-chain amino acids.

Bioengineering &amp; translational medicine
2025

Neuroprotective, antioxidant and anti-inflammatory effect of carnitine in patients with Maple syrup urine disease: branched-chain amino acids and branched-chain keto acids levels.

Metabolic brain disease
2026

A colorimetric strategy for quantifying amino acids using E. coli auxotrophs displaying gold-binding proteins.

Biosensors &amp; bioelectronics
2025

Building Equity Through Experience: Insights From 1560 Single-Center Pediatric Liver Transplants in a Developing Country.

Pediatric transplantation
2025

Insights from Metabolomics Profiling of MSUD in Pediatrics Toward Disease Progression.

Metabolites
2026

A risk-based, QTPP-driven framework for semi-solid extrusion 3d printing of personalized medicines: Integrating hospital compounding and clinical trial regulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
2025

Sniffing Out Skin Disease: Odors in Dermatologic Conditions.

Cutis
2025

Transplant Without Borders: Clinical Outcomes and Challenges in Transborder Living Donor Pediatric Liver Transplantation in Jordan.

Therapeutics and clinical risk management
2025

Adenine base editing rescues disrupted BCKDH function and reduces BCAAs toxic accumulation in maple syrup urine disease patient iPSC-hepatic organoids.

Stem cell research &amp; therapy
2025

From Crisis to Continuum: Redefining Survivorship in Neurometabolic Care.

Pediatric neurology
2025

Minocycline Protects Against Oxidative Stress in a Model of Maple Syrup Urine Disease.

Neurochemical research
2025

Two Countries, One Metabolic Dilemma: Nutritional Management of Concurrent Maple Syrup Urine Disease and Type 1 Diabetes Mellitus.

Journal of clinical research in pediatric endocrinology
2025

Thiamine-responsive maple syrup urine disease missed by newborn screen: A case report.

Molecular genetics and metabolism reports
2025

Altered branched chain ketoacids underlie shared metabolic phenotypes in type 1 diabetes and maple syrup urine disease.

Communications medicine
2025

HMG-CoA Synthase-2 Deficiency: Neonatal Hyperammonemic Coma and Abnormal Metabolic Screening Resembling Maple Syrup Urine Disease.

JIMD reports
2025

[Maple syrup urine disease decompensation - rare but life-threatening].

Praxis
2025

Are protein substitutes available in Italy for infants with inherited metabolic diseases all the same?

Frontiers in nutrition
2025

Assembly of Branched Chain Amino Acids to Toxic Fibrils may be Related to Pathogenesis of Maple Syrup Urine Disease.

Chembiochem : a European journal of chemical biology
2025

The Clinical and Biochemical Impact of the Multivitamin Shortage on Neonatal Patients.

Journal of investigative medicine high impact case reports
2025

Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency (DLDD): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients.

Journal of inherited metabolic disease
2025

Unlocking hope: domino liver transplantation for maple syrup syndrome, a single center experience work carried out at the King Fahad Specialist Hospital.

Frontiers in immunology
2025

Branched-chain amino acid transferase type 2 (BCAT2) deficiency: Report of an eighth case and literature review.

Molecular genetics and metabolism reports
2025

Nodular Regenerative Hyperplasia Is a Frequent Finding in Explanted Livers of Patients With Maple Syrup Urine Disease.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2025

Advancing the Biochemical Understanding of Maple Syrup Urine Disease and the Impact of Liver Transplantation: A Pilot Study.

Journal of proteome research
2025

Acute encephalopathy in a neonate: a diagnostic odyssey leading to maple syrup urine disease (MSUD).

BMJ case reports
2025

Spectrum of genetic variants associated with maple syrup urine disease in the Middle East, North Africa, and Türkiye (MENAT): a systematic review.

BMC medical genomics
2025

Short and Long-Term Outcomes of Liver Transplantation in Pediatric Patients With Inborn Errors of Metabolism: A Single-Center Study.

Pediatric transplantation
2025

Expanding the Genetic Spectrum of PPM1K-Related Maple Syrup Urine Disease: A Novel Mutation.

American journal of medical genetics. Part A
2025

Functional connectivity changes in mouse models of maple syrup urine disease.

Cerebral cortex (New York, N.Y. : 1991)
2025

BCKDHA-BCKDHB digenic gene therapy restores metabolic homeostasis in two mouse models and a calf with classic maple syrup urine disease.

Science translational medicine
2025

The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: 10 Years Later, Another Report From the SSIEM Adult Metabolic Physicians Group.

Journal of inherited metabolic disease
2025

Contribution of Brain Intrinsic Branched-Chain Amino Acid Metabolism in a Novel Mouse Model of Maple Syrup Urine Disease.

Journal of inherited metabolic disease
2025

The branched-chain amino acid-related isoleucic acid: recent research advances.

Plant biology (Stuttgart, Germany)
2025

α-Ketoisocaproic Acid Disrupts Mitochondrial Bioenergetics in the Brain of Neonate Rats: Molecular Modeling Studies of α-ketoglutarate Dehydrogenase Subunits Inhibition.

Neurochemical research
2025

Comprehensive Iranian guidelines for the diagnosis and management of maple syrup urine disease: an evidence- and consensus- based approach.

Orphanet journal of rare diseases
2025

Acrodermatitis dysmetabolica: lessons from two pediatric cases.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Factors associated with poor outcomes in patients with maple syrup urine disease in a tertiary government hospital: A retrospective cohort study.

JIMD reports
2025

Acute metabolic decompensation after liver transplant in a patient with maple syrup urine disease.

JIMD reports
2025

Phosphatase activity-based PPM1K: a key player in the regulation of mitochondrial function and its multifaceted impact in diseases.

Molecular and cellular biochemistry
2024

Living with a child with MSUD: Psychosocial issues of Filipino parents with a child with maple syrup urine disease.

Genetics in medicine open
2025

Integration of multi-omics layers empowers precision diagnosis through unveiling pathogenic mechanisms on maple syrup urine disease.

Journal of inherited metabolic disease
2025

Executive and adaptive function impacts long-term outcomes for adults with maple syrup urine disease.

Journal of inherited metabolic disease
2025

Assessment of quality of life in families affected by maple syrup urine disease: a cross sectional study.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2024

Maple syrup urine disease diagnosed in a resource-limited setting in an infant in Nepal: a case report.

BMC pediatrics
2025

Donepezil treatment mitigates cholinergic system alterations, oxidative stress, neuroinflammation and memory impairment induced by branched-chain amino acid administration in rats.

Behavioural brain research
2024

Expanding the genotypic and phenotypic spectrum of Egyptian children with maple syrup urine disease.

Scientific reports
2024

The Efficacy and Outcomes of Renal Replacement Therapy in Pediatric Metabolic Disorders.

Journal of clinical medicine
2024

Liquid chromatography-mass spectrometric method for the simultaneous analysis of branched-chain amino acids and their ketoacids from dried blood spot as secondary analytes for the detection of maple syrup urine disease.

Journal of mass spectrometry and advances in the clinical lab
2024

Exploring molecular spectrum in thai patients with maple syrup urine disease: unveiling a common variant.

Orphanet journal of rare diseases
2024

The Value of Reducing Inconclusive and False-Positive Newborn Screening Results for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Maple Syrup Urine Disease in The Netherlands.

International journal of neonatal screening
2025

Urine organic acid metabolomic profiling by gas chromatography mass spectrometry: Assessment of solvent extract evaporation parameters on the recovery of key diagnostic metabolites.

Clinica chimica acta; international journal of clinical chemistry
2025

Impact of early diagnosis, disease variant, and quality of care on the neurocognitive outcome in maple syrup urine disease: A meta-analysis.

Genetics in medicine : official journal of the American College of Medical Genetics
2024

Acceptability of dried blood spot collection by primary caregivers of Filipino patients with maple syrup urine disease (MSUD) and phenylketonuria (PKU).

Journal of community genetics
2024

Two Novel Mutations in the BCKDHB Gene Cause Intermediate Maple Syrup Urine Disease.

Annals of Indian Academy of Neurology
2024

Domino Liver Transplantation: Anesthetic Considerations for a Patient With Maple Syrup Urine Disease and Type I Diabetes Mellitus.

Cureus
2024

The Impact of Diet on Body Composition in a Cohort of Pediatric and Adult Patients with Maple Syrup Urine Disease.

Nutrients
2024

A comprehensive in silico analysis of mutation spectrum of maple syrup urine disease (MSUD) genes in Iranian population.

Molecular biology research communications
2024

Determination of the Protein and Amino Acid Content of Fruit, Vegetables and Starchy Roots for Use in Inherited Metabolic Disorders.

Nutrients
2024

Maple syrup urine disease diagnosis in Brazilian patients by massive parallel sequencing.

Molecular genetics and metabolism
2024

Long-Term Amino Acid Homeostasis, Neurodevelopmental and Growth Profiles Following Liver Transplantation in Maple Syrup Urine Disease.

Pediatric transplantation
2025

Seizure Characteristics and EEG Features in Intoxication Type and Energy Deficiency Neurometabolic Disorders in the Pediatric Intensive Care Unit: Single-Center Experience Over 10 Years.

Neurocritical care
2024

Expanding the Donor Pool to the Ultimate Level: Introducing the Revolutionary Hybrid Dual Graft Liver Transplant Using Domino and Living Donors.

Transplantation direct
2024

The natural history of dihydrolipoamide dehydrogenase deficiency in Israel.

Journal of inherited metabolic disease
2024

Lipid Nanoparticle mRNA Therapy Improves Survival and Reduces Serum Branched-Chain Amino Acids in Mouse Models of Maple Syrup Urine Disease.

Human gene therapy
2024

Treatment Outcomes for Maple Syrup Urine Disease Detected by Newborn Screening.

Pediatrics
2024

Size-Dependent Fullerenes for Enhanced Interaction of l-Leucine: A Combined DFT and MD Simulations Approach.

Langmuir : the ACS journal of surfaces and colloids
2024

Exploratory Untargeted Metabolomics of Dried Blood Spot Samples from Newborns with Maple Syrup Urine Disease.

International journal of molecular sciences
2024

Inborn errors of metabolism and pregnancy.

American journal of obstetrics &amp; gynecology MFM
2024

Genotypic and phenotypic spectrum of maple syrup urine disease in Zhejiang of China.

QJM : monthly journal of the Association of Physicians
2024

Identifying Metabolic Diseases That Precipitate Neonatal Seizures.

Neonatal network : NN
2024

Computational structural genomics and clinical evidence suggest BCKDK gain-of-function may cause a potentially asymptomatic maple syrup urine disease phenotype.

JIMD reports
2024

The interplay of psychosis and non-compliance with fatal outcome in an adult with MSUD.

American journal of medical genetics. Part A
2024

[Newborn screening in France: news and perspectives].

Annales de biologie clinique
2024

Space research to explore novel biochemical insights on Earth.

Clinica chimica acta; international journal of clinical chemistry
2024

The oral phenotype and dental management in patients with maple syrup urine disease; case report and scoping review.

BMC oral health
2024

Acute Encephalopathy in a 10-Year-Old Patient With Maple Syrup Urine Disease: A Challenging Diagnosis.

Cureus
2024

Odimet®: A Pioneering Tele-Health Tool to Empower Dietary Treatment and the Acute Management of Inborn Errors of Metabolism-An Assessment of Its Effectiveness during the COVID Pandemic.

Nutrients
2024

Acrodermatitis dysmetabolica with concomitant acquired acrodermatitis enteropathica in a patient with maple syrup urine disease.

JAAD case reports
2023

Acrodermatitis dysmetabolica secondary to isoleucine deficiency in infant with maple syrup urine disease.

Dermatology reports
2024

Successful adult domino living donor liver transplantation in methylmalonic acidemia: case report.

Translational gastroenterology and hepatology
2024

Changes in branched-chain amino acids in an infant with maple syrup urine disease during perioperative pediatric liver transplant: A case report.

Paediatric anaesthesia
2024

Pubertal origin of growth retardation in inborn errors of protein metabolism: A longitudinal cohort study.

Molecular genetics and metabolism
2024

Maple Syrup Urine Disease.

Radiology
2024

Liver-directed gene therapy for inherited metabolic diseases.

Journal of inherited metabolic disease
2023

Cardiac Involvement in Classical Organic Acidurias: Clinical Profile and Outcome in a Pediatric Cohort.

Diagnostics (Basel, Switzerland)
2024

Memantine Improves Memory and Neurochemical Damage in a Model of Maple Syrup Urine Disease.

Neurochemical research
2023

Analysis of Branched Amino Acids by UPLC as an Alternative Method for the Management of Patients with MUSD.

Clinical laboratory
2024

Metabolic crisis in maple syrup urine disease: an unusual complication of a rare disease: a case report.

Anaesthesia and intensive care
2023

Branched-Chain Amino Acid Assembly into Amyloid-like Fibrils Provides a New Paradigm for Maple Syrup Urine Disease Pathology.

International journal of molecular sciences
2024

In Vivo Intracerebral Administration of α-Ketoisocaproic Acid to Neonate Rats Disrupts Brain Redox Homeostasis and Promotes Neuronal Death, Glial Reactivity, and Myelination Injury.

Molecular neurobiology
2023

Investigation of the effect of vitamin K1 prophylaxis on newborn screenings tests in newborns.

Journal of medical biochemistry
2023

Evaluation of the risk factors for noncommunicable diseases in patients with inborn errors of amino acid metabolism receiving nutrition therapy.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2023

Fasting and non-fasting plasma levels of monomethyl branched chain fatty acids: Implications for maple syrup urine disease.

JIMD reports
2023

Domino liver transplantation for maple syrup urine disease in children: A single-center case series.

Pediatric transplantation
2023

Living Donor-Initiated Domino Split-Liver Transplantation in Pediatric Setup: A Case Report With Literature Review.

Transplantation proceedings
2023

Breastfeeding and Inborn Errors of Amino Acid and Protein Metabolism: A Spreadsheet to Calculate Optimal Intake of Human Milk and Disease-Specific Formulas.

Nutrients
2023

Inherited Metabolic Diseases from Past to Present: A Bibliometric Analysis (1968-2023).

Children (Basel, Switzerland)
2023

Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates.

Journal of inherited metabolic disease
2023

Maple Syrup Urine Disease: An Uncommon Cause of Neonatal Febrile Seizures.

Cureus
2023

Newborn screening of maple syrup urine disease and the effect of early diagnosis.

Clinica chimica acta; international journal of clinical chemistry
2023

The impact of liver transplantation on health-related quality of life in (acute) intoxication-type inborn errors of metabolism.

Journal of inherited metabolic disease
2023

Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2023

Outcomes from a Single Transplant Center of 5 Pediatric Cases of Domino Liver Transplantation from Live Donors with Maple Syrup Urine Disease.

Annals of transplantation
2023

Insulin Resistance and Impaired Branched-Chain Amino Acid Metabolism in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD
2023

Organic Aciduria Disorders in Pregnancy: An Overview of Metabolic Considerations.

Metabolites
2023

Melatonin improves behavioral parameters and oxidative stress in zebrafish submitted to a leucine-induced MSUD protocol.

Metabolic brain disease
2023

Twin Premature Infants With Riboflavin and Biotin Deficiency Presenting With Refractory Lactic Acidosis, Rash, and Multiorgan Failure During Prolonged Parenteral Nutrition.

Journal of investigative medicine high impact case reports
2023

Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.

Tremor and other hyperkinetic movements (New York, N.Y.)
2023

Identification of gene mutations in six Chinese patients with maple syrup urine disease.

Frontiers in genetics
2023

Acute effects of intracerebroventricular administration of α-ketoisocaproic acid in young rats on inflammatory parameters.

Metabolic brain disease
2024

Successful treatment of severe MSUD in Bckdhb-/- mice with neonatal AAV gene therapy.

Journal of inherited metabolic disease
2023

Diagnosis of an intermediate case of maple syrup urine disease: A case report.

World journal of clinical cases
2023

Knowledge-Based Dietary Intake Recommendations of Nutrients for Pediatric Patients with Maple Syrup Urine Disease.

Healthcare (Basel, Switzerland)
2023

Development of a Universal Second-Tier Newborn Screening LC-MS/MS Method for Amino Acids, Lysophosphatidylcholines, and Organic Acids.

Analytical chemistry
2023

PPM1K defects cause mild maple syrup urine disease: The second case in the literature.

American journal of medical genetics. Part A
2023

A Smart Monitoring System for Self-Nutrition Management in Pediatric Patients with Inherited Metabolic Disorders: Maple Syrup Urine Disease (MSUD).

Healthcare (Basel, Switzerland)
2023

Organic acidurias in Egyptian children: The urge for high-risk screening.

Pediatrics international : official journal of the Japan Pediatric Society
2023

Long-term results of liver transplantation for maple syrup urine disease: A single-center experience in Turkey.

Pediatric transplantation
2022

Neonatal maple syrup urine disease case report and literature review.

Medicine
2023

Leucine tolerance in children with MSUD is not correlated with plasma leucine levels at diagnosis.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Hyperammonemia in Russia Due to Carbonic Anhydrase VA Deficiency Caused by Homozygous Mutation p.Lys185Lys (c.555G>A) of the CA5A Gene.

International journal of molecular sciences
2022

Identification of Clinical Variants beyond the Exome in Inborn Errors of Metabolism.

International journal of molecular sciences
2022

Alternative sources of valine and isoleucine for prompt reduction of plasma leucine in maple syrup urine disease patients: A case series.

JIMD reports
2022

Maple syrup urine disease due to a paracentric inversion of chr 19 that disrupts BCKDHA: A case report.

JIMD reports
2023

Branched-chain amino acids (BCAA) administration increases autophagy and the autophagic pathway in brain tissue of rats submitted to a Maple Syrup Urine Disease (MSUD) protocol.

Metabolic brain disease
2022

Case report: NAFLD and maple syrup urine disease: Is there an interplay between branched-chain amino acids and fructose consumption?

Frontiers in pediatrics
2022

Dichloroacetate and thiamine improve survival and mitochondrial stress in a C. elegans model of dihydrolipoamide dehydrogenase deficiency.

JCI insight
2022

Utilizing augmented artificial intelligence for aminoacidopathies using collaborative laboratory integrated reporting- A cross-sectional study.

Annals of medicine and surgery (2012)
2023

Intestinal Mucormycosis in a Child With Maple Syrup Urine Disease After Orthotopic Liver Transplant.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
2022

Teaching NeuroImage: Optic Pathway Involvement in Maple Syrup Urine Disease.

Neurology
2022

Organic acidemias in the neonatal period: 30 years of experience in a referral center for inborn errors of metabolism.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2023

Safety of COVID-19 vaccines in children with inborn errors of metabolism in terms of developing metabolic decompensation.

Journal of paediatrics and child health
2022

Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review.

Biology
2022

Quantification of Branched-Chain Amino Acids in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Methods in molecular biology (Clifton, N.J.)
2022

Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.

Frontiers in pediatrics
2022

Exposure to leucine alters glutamate levels and leads to memory and social impairment in zebrafish.

Metabolic brain disease
2022

In-Hospital Mortality From Cerebral Edema in MSUD During Newborn Screening Era: What Are We Missing and What More Can We Do?

Pediatric neurology
2022

Comparison Between Dichloroacetate and Phenylbutyrate Treatment for Pyruvate Dehydrogenase Deficiency.

British journal of biomedical science
2022

The Role of Branched-Chain Amino Acids and Branched-Chain α-Keto Acid Dehydrogenase Kinase in Metabolic Disorders.

Frontiers in nutrition
2022

Usability of NewSTEPs Data for Assessing the Characteristics of Infants with Newborn Screening Disorders.

International journal of neonatal screening
2022

[Genetic analysis of two Chinese families with maple syrup urine disease].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2022

Genomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry.

American journal of medical genetics. Part A
2022

Domino liver transplant from a donor with maple syrup urine disease into a recipient with phenylketonuria.

Molecular genetics and metabolism reports
2022

Maple syrup urine disease decompensation misdiagnosed as a psychotic event.

Molecular genetics and metabolism reports
2022

Domino liver transplantation: Expanding the liver donor pool to the pediatric recipient.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2022

Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice.

Nature communications
2022

[Disease spectrum analysis of children with inherited metabolic diseases detected by gas chromatography-mass spectrometry of urinary organic acids].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2022

Pathogenic Homozygous Mutations in the DBT Gene (c.1174A>C) Result in Maple Syrup Urine Disease in a rs12021720 Carrier.

Laboratory medicine
2022

Quantitation of non-derivatized free amino acids for detecting inborn errors of metabolism by incorporating mixed-mode chromatography with tandem mass spectrometry.

Journal of mass spectrometry and advances in the clinical lab
2022

Treatment of COVID-19 in a Patient With Maple Syrup Urine Disease.

Cureus
2022

Molecular Genetic Screening of Neonatal Intensive Care Units: Hyperbilirubinemia as an Example.

The application of clinical genetics
2022

Development, validation, and uncertainty measurement of HPLC-DAD method for determination of some free amino acids in infant formula and medical food products for inborn errors of metabolism.

Food chemistry
2022

A rapid LC-MS/MS assay for detection and monitoring of underivatized branched-chain amino acids in maple syrup urine disease.

Journal of mass spectrometry and advances in the clinical lab
2022

Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study.

Orphanet journal of rare diseases
2022

Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids.

Neurochemistry international
2022

Machine learning approach identifies meconium metabolites as potential biomarkers of neonatal hyperbilirubinemia.

Computational and structural biotechnology journal
2022

Clinical diagnosis of metabolic disorders using untargeted metabolomic profiling and disease-specific networks learned from profiling data.

Scientific reports
2022

Coadministration of tianeptine alters behavioral parameters and levels of neurotrophins in a chronic model of Maple Syrup Urine disease.

Metabolic brain disease
2022

Integration of an Expression Platform in the SELEX Cycle to Select DNA Aptamer Binding to a Disease Biomarker.

ACS omega
2022

Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region.

JIMD reports
2022

Exposure to leucine induces oxidative stress in the brain of zebrafish.

Metabolic brain disease
2022

3.19 Inborn Errors of Metabolism.

World review of nutrition and dietetics
2022

Acute hemodialysis therapy in neonates with inborn errors of metabolism.

Pediatric nephrology (Berlin, Germany)
2022

A Gain-of-Function Mutation on BCKDK Gene and Its Possible Pathogenic Role in Branched-Chain Amino Acid Metabolism.

Genes
2022

Continuous veno-venous hemodiafiltration in neonates with maple syrup urine disease.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
2022

Screening of gene detection of monogenic inherited disorder in an infertile population in Henan Province: an autosomal recessive disorder carried by maple syrup urine disease.

Endokrynologia Polska
2022

Key patient-reported outcomes in children and adolescents with intoxication-type inborn errors of metabolism: an international Delphi-based consensus.

Orphanet journal of rare diseases
2022

Inborn error of metabolism patients after liver transplantation: Outcomes of 35 patients over 27 years in one pediatric quaternary hospital.

American journal of medical genetics. Part A
2022

Domino liver transplants: where do we stand after a quarter-century? A US national analysis.

HPB : the official journal of the International Hepato Pancreato Biliary Association
2022

Three novel mutations of the BCKDHA, BCKDHB and DBT genes in Chinese children with maple syrup urine disease.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Selective screening for inborn errors of metabolism by tandem mass spectrometry at Sohag University Hospital, Egypt.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2022

ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications.

Neuroscience and biobehavioral reviews
2023

Congenital Hyperinsulinism and Maple Syrup Urine Disease: A Challenging Combination.

Journal of clinical research in pediatric endocrinology
2021

Autism spectrum disorder in patients with inherited metabolic disorders-a large sample from a tertiary center.

The Turkish journal of pediatrics
2021

Screening for neonatal inherited metabolic disorders by tandem mass spectrometry in Guangzhou.

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
2022

Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.

Pediatric nephrology (Berlin, Germany)
2022

Surgical technique and the long-term outcomes of pediatric living donor domino liver transplantation from patients with maple syrup urine disease.

Pediatric transplantation
2021

The Effects of a Ketogenic Diet on Patients with Dihydrolipoamide Dehydrogenase Deficiency.

Nutrients
2021

Author Correction: Genetic analysis by targeted next-generation sequencing and novel variation identification of maple syrup urine disease in Chinese Han population.

Scientific reports
2021

Frequency and status of depression and anxiety in mothers of children with inborn errors of metabolism with restricted diet, with and without risk of metabolic crises.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2021

Genetic analysis by targeted next-generation sequencing and novel variation identification of maple syrup urine disease in Chinese Han population.

Scientific reports
2021

Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model.

Molecular genetics and metabolism
Ver todos os 842 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença da urina xarope de bordo.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença da urina xarope de bordo

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Assessing the nutritional value and health risks of special low&#x2011;protein foods: narrative review.
    Orphanet journal of rare diseases· 2026· PMID 41792796mais citado
  2. A risk-based, QTPP-driven framework for semi-solid extrusion 3d printing of personalized medicines: Integrating hospital compounding and clinical trial regulation.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences· 2026· PMID 41125146mais citado
  3. A case of maple syrup urine disease with infantile epileptic spasms syndrome: Challenges in a resource-limited setting.
    Pediatrics international : official journal of the Japan Pediatric Society· 2026· PMID 41708577mais citado
  4. Alterations in gut microbiota composition in children with methylmalonic acidemia, propionic acidemia, and maple syrup urine disease.
    European journal of clinical nutrition· 2026· PMID 41872585mais citado
  5. A Colorimetric Multimetabolite Assay for Quantitative Measurement of Keto Acids in Urine for At-Home Monitoring of Metabolic Disorders.
    Journal of analytical methods in chemistry· 2026· PMID 41767879mais citado
  6. Relationship of Filipino MSUD Children's Nutrient Intake, Nutritional Status, and Leucine Level, and Caregiver's Nutrition Knowledge, Attitudes, and Practices.
    Acta Med Philipp· 2026· PMID 41959848recente
  7. Simplifying supplementation in MSUD: tolerance and acceptability of liquid valine and isoleucine supplements in maple syrup urine disease.
    Orphanet J Rare Dis· 2026· PMID 41928300recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:511(Orphanet)
  2. MONDO:0009563(MONDO)
  3. GARD:3228(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q402575(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença da urina xarope de bordo
Compêndio · Raras BR

Doença da urina xarope de bordo

ORPHA:511 · MONDO:0009563
🇧🇷 Brasil SUS
Triagem
MS/MS (espectrometria de massas em tandem)
PNTN
Fase 2
Incidência BR
1:10.000 (coletivo)
Geral
Prevalência
1-9 / 1 000 000
Herança
Autosomal recessive
CID-10
E71.0 · Doença da urina em xarope de ácer (ou bordo) (Maple-syrup urine disease)
CID-11
Ensaios
5 ativos
Início
Childhood, Infancy, Neonatal
Prevalência
0.0 (Europe)
MedGen
UMLS
C0024776
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades